JUPITER, Fla. - Ligand Pharmaceuticals (NASDAQ:LGND) Incorporated (NASDAQ:LGND), a biopharmaceutical company with a market capitalization of $2.19 billion and an impressive 88% stock return over the past year, announced at its Investor and Analyst Day in Boston that it anticipates a 17% increase in revenue growth for the fiscal year 2025, projecting revenues between $180 million and $200 million. This growth is expected to be driven by twelve commercial-stage programs and a late-stage pipeline. According to InvestingPro data, the company currently trades near its Fair Value, with 11 additional exclusive insights available to subscribers.
The company's CEO, Todd Davis, and CFO, Tavo Espinoza, along with other senior management, outlined Ligand's transformation over the past two years into a profitable and diversified organization. They credited the company's robust financial performance in 2024 to a 27% increase in full-year royalty revenue and a 38% increase in full-year core adjusted earnings per diluted share. InvestingPro analysis reveals the company maintains an impressive 78.8% gross profit margin and receives a "GREAT" financial health score, demonstrating strong operational efficiency.
For 2025, Ligand expects royalty revenue to contribute between $135 million and $140 million, Captisol sales to account for $35 million to $40 million, and contract revenue to be in the range of $10 million to $20 million. The company also forecasts core adjusted earnings per diluted share to be between $6.00 and $6.25.
Ligand's long-term financial outlook includes a projection of at least a 22% compound annual growth rate in long-term royalty receipts, with total royalty receipts expected to reach approximately $285 million by 2029. The company's Captisol® and NITRICIL™ technology platforms are cited as key elements in generating significant revenue growth.
Key products contributing to Ligand's expected royalty revenue growth in 2025 include Filspari (Travere Therapeutics), Capvaxive ( Merck (NS:PROR)), Ohtuvayre (Verona Pharma (NASDAQ:VRNA) plc), Qarziba ( Recordati (BIT:RECI) S.p.A.), and Veklury (Gilead Sciences, Inc. (NASDAQ:GILD)). The company also highlighted its active dealmaking, having deployed $192 million across eight investments and evaluating over $1 billion in actionable opportunities.
This news is based on a press release statement from Ligand Pharmaceuticals. The company's financial guidance is subject to various risks and uncertainties, including the performance of its partners' products, the commercialization of its technology platforms, and the overall economic conditions. The company's adjusted financial measures are not a substitute for financial measures calculated in accordance with GAAP, and certain forward-looking non-GAAP measures cannot be provided without unreasonable effort due to their inherent variability. For comprehensive analysis including valuation metrics, financial health indicators, and expert insights, access the full Pro Research Report available exclusively on InvestingPro.
In other recent news, Ligand Pharmaceuticals has been making notable strides in its financial performance. The firm reported a significant 58% increase in total revenue year-over-year for the third quarter of 2024 and subsequently raised its revenue forecast for the year. This development comes as RBC Capital Markets upgraded its price target on Ligand shares to $141.00, maintaining an Outperform rating.
In addition to these financial highlights, Ligand has also been proactive in its strategic initiatives. The company is currently evaluating 25 potential investments, each with an average targeted investment size of $30 million to $40 million. These acquisitions, focused on late-stage and commercial assets, are expected to sustain Ligand's growth.
Ligand also reported successful product launches and FDA approvals, including Verona Pharma's Ohtuvayre and Merck's CAPVAXIVE, which are expected to significantly contribute to future royalty revenues. The company's Captisol, a solubility enhancer with 16 approved products, continues to hold a strong market position.
These are recent developments that reflect Ligand's robust financial health and strategic market approach. The company expects long-term royalty revenue growth at a compound annual rate of over 22%. An Investor Day is scheduled for December to provide an updated long-term outlook, as indicated by RBC Capital's analysis.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.